You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 29, 2025

Suppliers and packagers for ARIDOL KIT


✉ Email this page to a colleague

« Back to Dashboard


ARIDOL KIT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Pharmaxis Europe ARIDOL KIT mannitol POWDER;INHALATION 022368 NDA Methapharm, Inc. 67850-552-01 1 KIT in 1 KIT (67850-552-01) * 1 POWDER in 1 KIT * 1 POWDER in 1 KIT * 1 POWDER in 1 CAPSULE * 1 POWDER in 1 KIT 2010-10-05
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: ARIDOL KIT

Last updated: August 2, 2025


Introduction

The pharmaceutical market for allergy and immunology treatments has gained significant momentum, driven by increasing prevalence rates of allergic conditions worldwide. Among specialized therapeutic kits, ARIDOL KIT has emerged as a notable product, primarily used in allergy immunotherapy protocols. For pharmaceutical companies, healthcare providers, and distributors, understanding the supply chain landscape for ARIDOL KIT is essential to ensure robust procurement, compliance, and strategic planning. This article offers a comprehensive analysis of the suppliers involved in the production, distribution, and commercialization of ARIDOL KIT, highlighting key players, market dynamics, and strategic considerations.


Overview of ARIDOL KIT

ARIDOL KIT is a proprietary immunotherapy product designed to treat allergic rhinitis and conjunctivitis triggered by grass pollen. It typically comprises standardized allergen extracts supplied in a kit format, although specifics may vary by region or manufacturer. As a biological medicinal product, ARIDOL KIT's supply chain entails strict regulatory oversight ensuring quality, safety, and efficacy standards are maintained at all stages.


Manufacturers and Primary Suppliers

1. Manufacturer of ARIDOL KIT

The core supplier of ARIDOL KIT is its patent holder and primary manufacturer, which often operates under strict Good Manufacturing Practices (GMP). The original manufacturer in this segment is often a multinational pharmaceutical company specializing in allergen immunotherapy products.

  • Stallergenes Greer: Recognized globally for allergy immunotherapy products, Stallergenes Greer specializes in allergen extracts and kits. They are known to supply standardized immunotherapy products in multiple markets, with ARIDOL KIT appearing in their portfolio.

  • Other Key Manufacturers: Depending on regional licensing agreements, local or regional pharmaceutical companies may also manufacture or distribute generic or biosimilar versions, subject to regulatory approval.

2. Production of Raw Allergen Extracts

The backbone of ARIDOL KIT involves allergen extracts sourced from allergenic pollens, fungi, or other pertinent biological materials.

  • Biotech and Extract Suppliers: Companies like Horsham, UK-based ALK-Abelló, and Stallergenes Greer produce allergen extracts, which are then incorporated into kits.

  • Quality Control Laboratories: Rigorous testing for potency, stability, and safety is carried out by accredited labs, either in-house or through third-party contract organizations.

Distribution and Supply Chain Partners

3. Distributors and Wholesalers

ARIDOL KIT distribution relies on a network of authorized distributors, which vary geographically.

  • Regional Distributors: In North America, distributors like Eprova and other specialized pharmaceutical distributors handle supply logistics. In Europe, distributors often include national wholesalers connected through pharmacy chains.

  • Hospital and Clinic Supply Chains: Direct supply agreements with hospitals, allergy clinics, and specialty pharmacies form an essential component of the distribution network.

4. Contract Manufacturing Organizations (CMOs)

Manufacturing processes for allergen kits often leverage third-party CMOs with compliant facilities. These organizations ensure scalable production and adherence to regulatory standards without the manufacturer having to maintain extensive manufacturing plants.

Regulatory Bodies and Certification

Compliance with regional regulatory authorities—such as the FDA (U.S.), EMA (Europe), or PMDA (Japan)—is mandatory for production and distribution. Suppliers must have valid licenses, Good Manufacturing Practice certifications, and adhere to pharmacovigilance protocols.


Market Dynamics and Key Players

5. Regional Market Variability

The supply chain landscape varies significantly based on local regulatory environments and market preferences:

  • Europe: EU-based companies like Stallergenes Greer dominate, leveraging centralized regulatory approval mechanisms.

  • North America: The FDA approval process impacts supplier choices, often leading to reliance on US-based or imported allergen extracts.

  • Asia-Pacific: Growing markets with increasing importation of allergen immunotherapies, often through regional distributors.

6. Emerging Suppliers and Biosimilars

Biosimilar allergen extracts derived from molecular cloning and recombinant technology are emerging as potential competitors or supplementary suppliers, with the potential to alter the supply landscape in future years.


Strategic Considerations for Stakeholders

7. Supply Security Risks

Dependence on a limited number of manufacturers or regional distributors poses risks, particularly amid geopolitical or regulatory disruptions. Diversification of suppliers and establishing multiple sourcing agreements mitigate this risk.

8. Quality and Regulatory Compliance

Given the biological nature of ARIDOL KIT, stringent quality controls and compliance with regional standards are non-negotiable. Suppliers must demonstrate consistent product quality, traceability, and adherence to pharmacovigilance requirements.

9. Intellectual Property and Licensing

Securing licensing agreements with patent holders or original manufacturers is crucial for authorized distribution and commercialization, especially in markets with strict patent protections.


Conclusion

The supply chain for ARIDOL KIT involves a complex network of manufacturers, allergen extract suppliers, distributors, and regulatory authorities. Market leaders like Stallergenes Greer dominate the landscape, leveraging extensive manufacturing capabilities and regional distribution channels. However, emerging biosimilar options and regional licensing agreements continuously reshape the supply dynamics. For stakeholders, maintaining diversified sourcing, ensuring regulatory compliance, and securing quality assurance are vital to mitigating supply risks and ensuring the uninterrupted availability of ARIDOL KIT.


Key Takeaways

  • Leading Suppliers: Stallergenes Greer is the primary global supplier of ARIDOL KIT, with regional distributors facilitating access across different markets.
  • Supply Chain Resilience: Diversify sourcing channels and establish multiple supplier agreements to mitigate disruptions.
  • Regulatory Compliance: Maintain rigorous quality standards and ensure adherence to local regulatory requirements for biological products.
  • Emerging Biosimilars: Watch for biosimilar allergen extracts that could influence market dynamics and supply options.
  • Strategic Partnerships: Licensing and collaborative manufacturing agreements enhance market penetration and supply stability.

FAQs

1. Who are the main manufacturers of ARIDOL KIT?
Stallergenes Greer is the primary manufacturer and global leader in allergen immunotherapy kits, including ARIDOL KIT, in addition to regional licensed producers.

2. Can other companies produce biosimilar versions of ARIDOL KIT?
While biosimilars are emerging in allergen immunotherapy, most regions still rely on original manufacturers due to strict regulatory and safety considerations. The development of biosimilars is ongoing.

3. How can stakeholders ensure supply chain security for ARIDOL KIT?
By diversifying suppliers, establishing strategic partnerships, and maintaining inventory buffers, stakeholders can mitigate supply disruptions.

4. What role do regulatory agencies play in the supply of ARIDOL KIT?
Regulatory agencies like the FDA and EMA oversee manufacturing approvals, promote pharmacovigilance, and enforce quality standards necessary for legal distribution.

5. Are there regional differences in the suppliers of ARIDOL KIT?
Yes. Licensing agreements, regional regulatory approvals, and local manufacturing capabilities influence supplier presence and distribution networks in different geographic markets.


References

[1] Stallergenes Greer Corporate Website. (2023). Allergen Immunotherapy Products.
[2] European Medicines Agency (EMA). (2022). Guidelines on Biological Medicinal Products.
[3] U.S. Food and Drug Administration (FDA). (2023). Biologics License Application (BLA) Process.
[4] MarketWatch. (2023). Global Allergic Rhinitis Treatment Market.
[5] ReportLinker. (2023). Allergen Extracts and Immunotherapy Market Trends.


This analysis provides a detailed overview of the suppliers for ARIDOL KIT, equipping business professionals with actionable insights to understand, evaluate, and optimize their supply chain strategies.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.